000			02062na a2200229 4500
003			H12O
005			20180417112628.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9431 _aGrávalos Castro, Cristina _eOncología Médica
245	0	0	_aRecommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain _h[artículo]
260			_bClinical & Translational Oncology, _c2011
300			_a13(12):862-868.
500			_aFormato Vancouver: Grávalos C, García-Alfonso P, Afonso R, Arrazubi V, Arrivi A, Cámara JC, et al. Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain. Clin Transl Oncol. 2011;13(12):862-8.
501			_aPMID: 22126729
504			_aContiene 68 referencias
520			_aIn Spain 22,000 new cases of colorectal cancer are diagnosed each year, with 13,075 deaths resulting from this disease. Around 70% of colorectal cancers are localised in the colon and 30% in the rectum. A group of Spanish experts established recommendations on what would be the best strategy in the treatment of locally advanced rectal cancer (LARC). Adequate assessment of local tumour extension, including high-resolution magnetic resonance imaging and endorectal ultrasound, is essential for successful treatment. The three cornerstones in the treatment of LARC are surgery, radiotherapy and chemotherapy. Most patients will need a total mesorectal excision (TME). Preoperative chemo-radiotherapy (CRT) is preferred for the majority of patients with T3/T4 disease and/or regional node involvement, and adjuvant chemotherapy is recommended after a patient-sharing decision. Capecitabine, after showing a trend in improved downstaging in neoadjuvant stratum and the convenience of its oral administration, represents an alternative to 5-FU as perioperative treatment of LARC.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/7/pc7673.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c7673 _d7673